Angiex presents preclinical data at AACR Special Conference in Cancer Research

17 November 2024

Angiex presented preclinical data for AGX101 at The AACR Special Conference In Cancer Research: Tumor-Body Interactions: The Roles of Micro- and Macroenvironment in Tumor Heterogeneity, Metastasis, and Therapy Response, held in Boston, Massachusetts on November 17-20, 2024.

The poster presentation, titled “AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial,” was presented by Angiex Chief Medical Officer Glen Weiss, M.D., on behalf of his co-authors: Principal Investigators I. Ismael Rodriguez Rivera, M.D. of NEXT Oncology; Meredith S. Pelster, M.D. of Sarah Cannon Research Institute; and Angiex founders Paul and Shou-Ching Jaminet.

The abstract has been published in the AACR journal Cancer Research, here. Citation: Ildefonso Ismael Rodriguez Rivera, Meredith S. Pelster, Shou-Ching Jaminet, Paul Jaminet, Glen J. Weiss. AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer; 2024 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2024;84(22_Suppl):Abstract nr C047.

Download the poster here:
angiex-aacr-poster-nov2024.pdf

Key insights from the poster

TM4SF1: a new target for oncology therapies

TM4SF1 has emerged as a promising target for antibody-drug conjugate (ADC) therapies. Its high expression in most solid tumors and a novel internalization pathway enabling direct drug delivery to the nucleus make it an ideal candidate for targeted treatments.

AGX101’s dual mechanism of action

Angiex’s first-in-class ADC, AGX101, combines two mechanisms: killing tumor cells directly and attacking the tumor vasculature to deprive cancers of their blood supply. This dual approach represents a novel direction for anti-angiogenic therapy.

Preclinical success

AGX101 demonstrated effectiveness across diverse preclinical models, highlighting its potential to address a wide range of solid tumors. These findings support its ongoing clinical evaluation.

Leadership in TM4SF1-directed ADCs

Angiex is leading the field in TM4SF1-directed ADCs, with AGX101 currently dosing patients in a first-in-human clinical trial.


About Angiex

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex...